Conflict of interest statement: Jason Lickliter and Mark Voskoboynik are 
employees of Nucleus Network (Australia). Jianjun Zou, Lianshan Zhang and Stacey 
Luo are employees of Jiangsu Hengrui Medicine Co. Ltd (China). Michael Lahn, 
Andrea Mannucci and Catello Somma were or are employees of Incyte Biosciences 
International Sarl (Switzerland). Howard Kallender is employee of Incyte 
Corporation (USA). Michael Millward and Tarek Meniawy are employees of Linear 
Clinical Research (Australia). Hui K. Gan reports receiving honoraria from 
speaker bureau of Bristol-Myers Squibb, Ignyta, Eisai and Merck Serono and is a 
consultant/advisory board member of AbbVie and Bristol-Myers Squibb. Andrea 
Mannucci has ownership interests (including stock, patents, etc.) at Incyte 
Biosciences International Sarl (Switzerland). Michael Millward has been or 
currently is a member of consultant/advisory board of Merck Sharp & Dohme, 
Novartis, Bristol-Myers Squib, Roche, AstraZeneca, and Pfizer, and has received 
travel support from Bristol-Myers Squibb and Roche. Adnan Nagrial is a member of 
consultant/advisory board of Bristol-Myers Squibb, Merck Sharpe Dohme, Astra 
Zeneca and Roche, and reports receiving speaking fees from Bristol-Myers Squibb, 
Merck Sharpe Dohme and Roche. Andreas Behren receives research support from 
Incyte (Switzerland) for the RO assay. Michael Lahn has ownership interests 
(including stock, patents, etc.) at Incyte Biosciences International Sarl 
(Switzerland), AstraZeneca and Eli Lilly. Surein Arulananda reports receiving 
personal fees from Merck Sharpe Dohme, Astra Zeneca, Roche and 
Boehringer-Ingelheim. Pablo Fernandez Penas is member of advisory committee (AC) 
or lecture (L, only educational, non-promotional lectures) of Janssen (AC, L), 
Lilly (AC, L), Abbvie (AC, L), Novartis (AC, L), UCB (L), MSD (AC), La Roche 
Posay (L), Merck (AC, L), Roche (AC, L), Amgen (L), Sun Pharma (AC, L), Sanofi 
(AC), Leo (AC, L), Avene (L), Celgene (AC), Galderma (L) and Schering Plough 
(L), and reports receiving clinical trial supports from Boehringer Ingelheim, 
Pfizer, CSL, OncoSec, Lilly, CBP, Abbvie, miRagen, Galderma, Regeneron, BMS, 
Eisai, Jiangsu Hengrui, Sun Pharma, Novartis, UCB, Leo, Janssen, Arena, Akaal 
Pharma, Roche, Xoma, Kyowa Hakko Kirin, GSK, Amgen and Merck Sharpe Dohme. No 
potential conflicts of interest were disclosed by other authors.